.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,354,948

« Back to Dashboard

Details for Patent: 7,354,948

Title:Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)eth- yl]-3-oxoisoindoline-4-yl}carboxamide
Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Nov 06, 2003
Application Number:10/534,325
Claims:1. A method of treating chronic uveitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)eth- yl]-3-oxoisoindoline-4-yl}carboxamide, which has the following structure: ##STR00033## or a pharmaceutically acceptable salt, or solvate thereof.

2. A method of treating chronic uveitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)eth- yl]-3-oxoisoindoline-4-yl}carboxamide, which has the following structure: ##STR00034## or a pharmaceutically acceptable salt, or solvate thereof, and a therapeutically effective amount of a second active ingredient.

3. The method of claim 2, wherein the second active ingredient is cytokine, anti-cancer agent, cox-2 inhibitor, or a combination thereof.

4. The method of claim 2, wherein the second active ingredient is oblimersen, melphalan, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, taxotere, irinotecan, a COX-2 inhibitor, ciprofloxacin, dexamethasone, doxorubicin, vincristine, IL 2, IFN, dacarbazine, Ara-C, vinorelbine, isotretinoin, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or a combination thereof.

5. The method of claim 1 or 2, wherein the compound is enantiomerically pure.

6. The method according to claim 1 or 2, wherein the compound is administered in an amount of from about 1 to about 10,000 mg per day.

7. The method of claim 6, wherein the compound is administered in an amount of about 10, 25, 50, 100, 200 or 300 mg per day.

8. The method of claim 6, wherein the compound is orally administered.

9. The method of claim 6, wherein the compound is administered in a capsule.

10. The method of claim 9, wherein the compound is administered in 50 mg or 100 mg of a capsule.

11. The method of claim 6, wherein the compound is topically administered.

12. The method of claim 11, wherein the compound is administered in a spray, aerosol, solution, suspension or eye drop.

13. The method of claim 3, wherein the second active ingredient is prednisone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc